Rilpivirine: drug profile of a second-generation non-nucleoside reverse transcriptase HIV-inhibitor
Authors:
- Enrico BombanaEBEnrico Bombana
- Marco RizziMRMarco Rizzi
- 28 November 2013
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Anti-infective Therapy
- Vol. 12 (1) , 13-29
Abstract
Rilpivirine (RPV) is a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) of the diarylpyrimidine family. RPV can be given once daily, is well absorbed and should be administered with food. It is eliminated mainly by hepatic metabolism. Two phase III noninferiority trials (ECHO and THRIVE), compared RPV 25mg with efavirenz (EFV) 600 mg, both given once daily, and combined with 2NRTI backbone. At week 48, response rate for pooled data were 84 versus 82% (difference: 2%; 95% CI: -2.0 to 6.0%). EFV arms performed better than RPV arms when at higher baseline HIV RNA, so RPV was approved for treatment-naïve patients with HIV RNA below 100,000 copies/ml. Approximately 90% of viruses phenotypically resistant to RPV showed cross-resistance to ETR. Conversely, phenotypic analysis showed that in EFV arm, none were resistant to the second-generation NNRTIs. CD4 count increases were similar between groups, but RPV showed a lower rate of discontinuation due to adverse events and lower rates of central nervous system effects, rash and lipid abnormalities. Potency, tolerability and co-formulation in a single tablet (Eviplera(®), Complera(®)) make this drug a new and attractive option for the treatment of HIV.Keywords
This publication has 33 references indexed in Scilit:
- Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trialThe Lancet, 2011
- Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trialThe Lancet, 2011
- Antiretroviral release from poly(DL-lactide-co-glycolide) nanoparticles in miceJournal of Antimicrobial Chemotherapy, 2010
- Pharmacokinetics and Disposition of Rilpivirine (TMC278) Nanosuspension as a Long-Acting Injectable Antiretroviral FormulationAntimicrobial Agents and Chemotherapy, 2010
- TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1Antimicrobial Agents and Chemotherapy, 2010
- Molecular Dynamics Study of Non-nucleoside Reverse Transcriptase Inhibitor 4-[[4-[[4-[(E)-2-Cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (TMC278/Rilpivirine) Aggregates: Correlation between Amphiphilic Properties of the Drug and Oral BioavailabilityJournal of Medicinal Chemistry, 2009
- High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: Strategic flexibility explains potency against resistance mutationsProceedings of the National Academy of Sciences, 2008
- Short-term antiviral activity of TMC278 – a novel NNRTI – in treatment-naive HIV-1-infected subjectsAIDS, 2006
- Modulation of Human Immunodeficiency Virus Type 1 Synergistic Inhibition by Reverse Transcriptase MutationsBiochemistry, 2006
- A Series of Diaryltriazines and Diarylpyrimidines Are Highly Potent Nonnucleoside Reverse Transcriptase Inhibitors with Possible Applications as MicrobicidesAntimicrobial Agents and Chemotherapy, 2004